Principal Investigator
Peter Hosein
Enrollment Status
Not Accepting
Clinical Trial ID
Institutional Protocol #
20220171
Clinical Trial Summary
A phase 1 trial of combined MEK, STAT3 and PD-1 inhibition in metastatic pancreatic ductal adenocarcinoma
Phase
Phase I
Funding Agency/Sponsor
Institutional
Disease
Pancreatic, Liver, and Related Cancers
Contact Information
Phone Number
305-243-2647